Engineered PLGA nanoparticles: An emerging delivery tool in cancer therapeutics

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 28, Issue 1, 2011, Pages 1-45

  Jain, Amit K ^a   Das, Manasmita ^a   Swarnakar, Nitin K ^a   Jain, Sanyog ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cancer targeting; Cancer therapy; PLGA nanoparticles

Indexed keywords

6 COUMARIN; AE 941; BEVACIZUMAB; CELECOXIB; CISPLATIN; COUMARIN DERIVATIVE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETARACIZUMAB; ETOPOSIDE; FOLIC ACID; GEFITINIB; IMATINIB; MITHRAMYCIN; NANOCARRIER; NANOPARTICLE; OLIGONUCLEOTIDE; PACLITAXEL; POLYGLACTIN; QUERCETIN; RALOXIFENE; ROFECOXIB; RUBITECAN; SMALL INTERFERING RNA; TAMOXIFEN; TRASTUZUMAB; TUMSTATIN; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ADENOMATOUS POLYP; BREAST CANCER; CANCER THERAPY; CIRCULATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE DELIVERY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NANOTECHNOLOGY; NONHUMAN; REVIEW;

EID: 79955648519     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i1.10     Document Type: Review

References (167)

1. Buell P, Dunn JE Jr. Cancer mortality among Japanese issei and nisei of California. Cancer. 1965 May;18:656-64.
2. Pollan M. The omnivore's dilemma: a natural history of four meals. New York: Penguin Press; 2006.
3. Wattenberg LW. Chemoprevention of cancer. Cancer Res. 1985;45(1):1-8.
4. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-45.
5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM. The infl uence of fi nasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-24.
6. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci. 2003;48(10):1998-2002.
7. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3): 161-71.
8. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-26.
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
10. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6(9):688-701.
11. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60.
12. Upadhyay KK, Le Meins JF, Misra A, Voisin P, Bouchaud V, Ibarboure E, Schatz C, Lecommandoux S. Biomimetic doxorubicin loaded polymersomes from hyaluronan-block-poly(gamma-benzyl glutamate) copolymers. Biomacromolecules. 2009;10(10):2802-8.
13. Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, Le Meins JF, Farooque A, Chandraiah G, Jain AK, Misra A, Lecommandoux S. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly ([gamma]-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials. 2010;31(10):2882-92.
14. Discher DE, Ahmed F. Polymersomes. Annu Rev Biomed Eng. 2006;8:323-41.
15. Kreuter J, Higuchi T. Improved delivery of methoxsalen. J Pharm Sci. 1979;68(4):451-4.
16. Batrakova EV, Dorodnych TY, Klinskii EY, Kliushnenkova EN, Shemchukova OB, Goncharova ON, Arjakov SA, Alakhov VY, Kabanov AV. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br J Cancer. 1996;74(10):1545-52.
17. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A. 2003;100(23):13549-54.
18. Sokolov K, Follen M, Aaron J, Pavlova I, Malpica A, Lotan R, Richards-Kortum R. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 2003;63(9):1999.
19. Kato K, Hamaguchi T, Yasui H, Okusaka T, Ueno H, Ikeda M, Shirao K, Shimada Y, Nakahama H, Muro K. Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. J Clin Oncol. 2006;24(18):2018.
20. Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther. 2006;8(1):399-435.
21. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750-63.
22. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6(7):559-65.
23. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008;16(2):108-23.
24. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-51.
25. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;68(16):6652.
26. Kam NWS, O'Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U S A. 2005;102(33):11600-5.
27. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. J Control Rel. 2008;125(3):193-209.
28. Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325-41.
29. Avgoustakis K. Pegylated poly (lactide) and poly (lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv. 2004;1(4):321-33.
30. Shubik P. Vascularization of tumors: a review. J Cancer Res Clin Oncol. 1982;103(3):211-26.
31. Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res. 1999;16(7):1114-8.
32. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller RH. 'Stealth'corona-core nanoparticles surface modifi ed by polyethylene glycol (PEG): infl uences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-13.
33. Bae YH. Drug targeting and tumor heterogeneity. J Control Release. 2009 Jan 5;133(1):2-3.
34. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17(3):247-89.
35. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422.
36. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MNV. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009;26(3):492-501.
37. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanopreci-pitation: drug loading and release studies of a water soluble drug. J Control Rel. 1999;57(2):171-85.
38. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Rel. 2002;79(1-3):123-35.
39. Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, Levy RJ. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Rel. 1997;43(2-3):197-212.
40. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opinion Solid State Mate Sci. 2002;6(4):319-27.
41. Jain AK, Swranakar NK, Chandraiah G, Preet SR, Jain S. The effect of the oral administration of polymeric nanoparticles on the effi cacy and toxicity of tamoxifen. Biomaterials. 2011;32:503-515.
42. Jain S, Mittal A, Jain AK, Mahajan RR, Singh D. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Current Nanosci. 2010; 6(4):422-431.
43. Dong Y, Feng SS. Poly (D, L-lactide-co-glycolide)(PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm. 2007;342(1-2):208-14.
44. Mo Y, Lim LY. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Rel. 2005;108(2-3):244-62.
45. Bilati U, Allémann E, Doelker E. Poly (D, L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method--processing and formulation issues for enhanced entrapment effi ciency. J Microencapsul. 2005;22(2):205-14.
46. Billon A, Chabaud L, Gouyette A, Bouler JM, Merle C. Vancomycin biodegradable poly (lactide-co-glycolide) microparticles for bone implantation. Infl uence of the formulation parameters on the size, morphology, drug loading and in vitro release. J Microencapsul. 2005;22(8):841-52.
47. Cegnar M, Premzl A, Zavasnik-Bergant V, Kristl J, Kos J. Poly (lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp Cell Res. 2004;301(2):223-31.
48. Moreno D, de Ilarduya CT, Bandrés E, Buñuales M, Azcona M, García-Foncillas J, Garrido MJ. Characterization of cisplatin cytotoxicity delivered from PLGA-systems. Eur J Pharm Biopharm. 2008;68(3):503-12.
49. Fonseca C, Simões S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemi-cal characterization and in vitro anti-tumoral activity. J Control Release. 2002;83(2):273-86.
50. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):R1-R4.
51. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipi-tation: drug loading and release studies of a water soluble drug. J Control Release. 1999;57(2):171-85.
52. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanopreci-pitation: preparation, characterization and in vitro evaluation. Nanomedicine. 2007;2(2):219-32.
53. Cohen-Sela E, Teitlboim S, Chorny M, Koroukhov N, Danenberg HD, Gao J, Golomb G. Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity. J Pharm Sci. 2009;98(4):1452-62.
54. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, Cai Z, Li Y, Chen Q. Dual agents loaded PLGA nano-particles: Systematic study of particle size and drug entrapment effi ciency. Eur J Pharm Biopharm. 2008;69(2):445-53.
55. Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q, Li Y, Hou S. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment effi ciency. Int J Pharm. 2008;350(1-2):320-9.
56. Manchanda R, Fernandez-Fernandez A, Nagesetti A, McGoron AJ. Preparation and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with simultaneous incorporation of chemotherapeutic and thermo-optical agents. Colloids Surf B Biointerfaces. 2010;75(1):260-7.
57. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm. 2008;5(4):516-26.
58. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982): 487-92.
59. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-76.
60. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv. 2006;3(3):311-24.
61. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008;105(7):2586-91.
62. Lu W, Tan YZ, Hu KL, Jiang XG. Cationic albumin conjugated pegylated nanoparticle with its trans-cytosis ability and little toxicity against blood-brain barrier. Int J Pharm. 2005;295(1-2):247-60.
63. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev. 2009;109(1):49-87.
64. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, Préat V. Pacli-taxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Rel. 2009;133(1):11-7.
65. Gryparis EC, Mattheolabakis G, Bikiaris D, Avgoustakis K. Effect of conditions of preparation on the size and encapsulation properties of PLGA-mPEG nanoparticles of cisplatin. Drug Delivery. 2007;14(6):371-80.
66. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cispla-tin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm. 2007;67(1):1-8.
67. Senthilkumar M, Mishra P, Jain NK. Long circulating PEGylated poly (D, L-lactide-co-glycolide) nanoparticulate delivery of docetaxel to solid tumors. J Drug Target. 2008;16(5):424-35.
68. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491-504.
69. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, Farokhzad OC. PLGA-lecithin PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30(8):1627-34.
70. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH. Direct comparison of lipo-somal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice. Clin Cancer Res. 1999;5(11):3645-52.
71. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modifi ed with monoclonal antibody. J Control Rel. 2007;120(1-2):18-26.
72. Kou G, Gao J, Wang H, Chen H, Li B, Zhang D, Wang S, Hou S, Qian W, Dai J. Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J Biochem Mol Biol. 2007;40(5):731-9.
73. Sun B, Ranganathan B, Feng SS. Multifunctional poly (D, L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials. 2008;29(4):475-86.
74. Gao J, Kou G, Chen H, Wang H, Li B, Lu Y, Zhang D, Wang S, Hou S, Qian W. Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly (lactic-co-glyco-lic acid) nanoparticles conjugated with humanized SM5-1 F (ab) fragments. Mol Cancer Ther. 2008;7(10):3399-407.
75. Folkman J. Fighting cancer by attacking its blood supply. Scientifi c American. 1996;275(3): 150-6.
76. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci. 2004;25(10):536-42.
77. Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol. 2004;14(2):139-45.
78. Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, Jérôme C, Marchand-Brynaert J, Feron O, Préat V. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J Control Release. 2009;140(2):166-73.
79. Wang Z, Chui WK, Ho PC. Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm Res. 2009;26(5):1162-71.
80. Luo G, Yu X, Jin C, Yang F, Fu D, Long J, Xu J, Zhan C, Lu W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm. 2009;385(1-2):150-6.
81. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski Jr VR, Kamen BA. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52(12):3396-401.
82. Farber S, Cutler EC, Hawkins JW, Harrison JH, Peirce EC 2nd, Lenz GG. The action of pteroylglu-tamic conjugates on man. Science. 1947;106(2764):619-21.
83. Garin-Chesa P, Campbell I, Saigo PE, Lewis Jr JL, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specifi city in immunopathology and molecular identifi cation as a folate-binding protein. Am J Pathol. 1993;142(2):557-67.
84. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994 May 1;73(9):2432-43.
85. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M, Atyabi F. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT29 cell lines. Nanomedicine. 2010;6(3):478-85.
86. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, Baker JRJ. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem. 2005;48(11): 3729-35.
87. Choi Y, Thomas T, Kotlyar A, Islam MT, Baker JR. Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specifi c targeting. Chem Bio. 2005;12(1):35-43.
88. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological signifi cance. Adv Drug Deliv Rev. 2001;47(1):113-31.
89. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56(8):1177-92.
90. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxor-ubicin via folate-targeted liposomes with bypass of multidrug-resistance effl ux pump. Clin Cancer Res. 2000;6(5):1949-57.
91. Hattori Y, Ding W, Maitani Y. Highly effi cient cationic hydroxyethylated cholesterol-based nano particle-mediated gene transfer in vivo and in vitro in prostate carcinoma PC-3 cells. J Control Rel. 2007;120(1-2):122-30.
92. Konda SD, Wang S, Brechbiel M, Wiener EC. Biodistribution of a 153Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest Radiol. 2002;37(4):199-204.
93. Shenoy D, Little S, Langer R, Amiji M. Poly (ethylene oxide)-modifi ed poly (-amino ester) nano-particles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 2. in vivo distribution and tumor localization studies. Pharm Res. 2005;22(12):2107-14.
94. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59(8):748-58.
95. Kim SH, Jeong JH, Chun KW, Park TG. Target-specifi c cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir. 2005;21(19):8852-7.
96. Zhang Z, Huey Lee S, Feng SS. Folate-decorated poly (lactide-co-glycolide)-vitamin E TPGS nano-particles for targeted drug delivery. Biomaterials. 2007;28(10):1889-99.
97. Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, Amini M, Dinar-vand R. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 2008;16(5):415-23.
98. Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W. Applications of aptamers in cancer cell biology. Anal Chim Acta. 2008;621(2):101-108.
99. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1(2):182-8.
100. White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest. 2000;106(8):929-34.
101. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu Rev Med. 2004;56:555-83.
102. Wilson C, Szostak JW. Isolation of a fl uorophore-specifi c DNA aptamer with weak redox activity. Chem Biol. 1998;5(11):609-17.
103. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R, editors. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-6320.
104. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356-61.
105. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated pacli-taxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005;2(5):373-83.
106. Zheng Y, Yu B, Weecharangsan W, Piao L, Darby M, Mao Y, Koynova R, Yang X, Li H, Xu S, Lee LJ, Sugimoto Y, Brueggemeier RW, Lee RJ. Transferrin-conjugated lipid-coated PLGA nanoparti-cles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells: International Journal of Pharmaceutics, 2010, 390, pp 234-241.
107. Yadav AK, Mishra P, Mishra AK, Jain S, Agrawal GP. Development and characterization of hyaluro-nic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine. 2007;3(4):246-57.
108. Lee H, Ahn CH, Park TG. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specifi c delivery of doxorubicin. Macromol Biosci. 2009;9(4):336-42.
109. Sonsoles D, Gemma N, Conchita Tros de I. In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med. 2009;11(1):38-45
110. Bowles NE, Eisensmith RC, Mohuiddin R, Pyron M, Woo SLC. A simple and effi cient method for the concentration and purifi cation of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum Gene Ther. 1996;7(14):1735-42.
111. Kitten O, Cosset FL, Ferry N. Highly effi cient retrovirus-mediated gene transfer into rat hepatocytes in vivo. Hum Gene Ther. 1997;8(12):1491-4.
112. Tsuchiyama T, Kaneko S, Nakamoto Y, Sakai Y, Honda M, Mukaida N, Kobayashi K. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Therapy. 2003;10(4):260-9.
113. Gerolami R, Uch R, Faivre J, Garcia S, Hardwigsen J, Cardoso J, Mathieu S, Bagnis C, Brechot C, Mannoni P. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol. 2004;40(2):291-7.
114. Cotten M, Wagner E, Zatloukal K, Phillips S, Curiel DT, Birnstiel ML. High-effi ciency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci U S A. 1992;89(13):6094-98.
115. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K. Coupling adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci U S A. 1992; 89:6099-103.
116. Hara T, Tan Y, Huang L. In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel non-viral vector. Proc Natl Acad Sci U S A. 1997;94(26):14547-52.
117. Cheng L, Ziegel Hoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A. 1993;90(10):4455-9.
118. Yoshida Y, Kobayashi E, Endo H, Hamamoto T, Yamanaka T, Fujimura A, Kagawa Y. Introduction of DNA into rat liver with a hand-held gene gun: distribution of the expressed enzyme,[32P] DNA, and Ca2+ fl ux. Biochem Biophys Res Commun. 1997;234(3):695-700.
119. Suzuki T, Shin BC, Fujikura K, Matsuzaki T, Takata K. Direct gene transfer into rat liver cells by in vivo electroporation. FEBS letters. 1998;425(3):436-40.
120. Wu J, Zern MA. Modifi cation of liposomes for liver targeting. J Hepatol. 1996;24(6):757-63.
121. Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009;15(23):7299-308.
122. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004;32(19):e149.
123. Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm. 2004;1(3):211-9.
124. He Q, Liu J, Sun X, Zhang ZR. Preparation and characteristics of DNA-nanoparticles targeting to hepatocarcinoma cells. World J Gastroenterol. 2004;10(5):660-3.
125. Koby G, Ofra B, Dganit D, Marcelle M. Poly (D, L-lactide-co-glycolide acid) nanoparticles for DNA delivery: Waiving preparation complexity and increasing effi ciency. Biopolymers. 2007;85(5-6):379-91.
126. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007;3(3):173-83.
127. Díez S, Miguéliz I, Tros de Ilarduya C. Targeted cationic poly (D, L-lactic-co-glycolic acid) nano-particles for gene delivery to cultured cells. Cell Mol Biol Lett. 2009;14(2):347-62.
128. Sioud M. On the delivery of small interfering RNAs into mammalian cells. Expert Opin. Drug Deliv. 2005;2(4):639-51.
129. Zhang S, Zhao B, Jiang H, Wang B, Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Rel. 2007;123(1):1-10.
130. Nguyen J, Steele TWJ, Merkel O, Reul R, Kissel T. Fast degrading polyesters as siRNA nano-carri-ers for pulmonary gene therapy. J Control Rel. 2008;132(3):243-51.
131. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm. 2009;367(1-2):195-203.
132. Feng SS, Mei L, Anitha P, Gan CW, Zhou W. Poly (lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials. 2009;30(19):3297-306.
133. Van Asperen J, Van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer. 1997;76(9):1181-3.
134. Kuppens I, Bosch TM, Van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JHM. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol. 2005;55(1):72-8.
135. Feng SS, Mei L, Anitha P, Gan CW, Zhou W. Poly (lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials2009;30:3297-306.
136. Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharm Res. 2007;55(1):1-15.
137. Kartner N, Ling V. Multidrug resistance in cancer. Sci Am. 1989;260(3):44-51.
138. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in infl uencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11(4):265-83.
139. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.
140. Hubensack M, Müller C, Höcherl P, Fellner S, Spruss T, Bernhardt G, Buschauer A. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol. 2008;134(5):597-607.
141. Bebawy M, Sze DM. Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics. Curr Cancer Drug Targets. 2008;8(1):47-52.
142. Florence AT. The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm Res. 1997;14(3):259-66.
143. Frey A, Giannasca KT, Weltzin R, Giannasca PJ, Reggio H, Lencer WI, Neutra MR. Role of the glyco-calyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med. 1996;184(3):1045-59.
144. Mantis NJ, Frey A, Neutra MR. Accessibility of glycolipid and oligosaccharide epitopes on rabbit villus and follicle-associated epithelium. Am J Physiol Gastrointest Liver Physiol. 2000;278(6):G915-23.
145. Clark M, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001;50(1-2):81-106.
146. Win K Y, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nano-particles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713-22.
147. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24(12):1113-28.
148. Dong Y, Feng SS. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004;25(14):2843-9.
149. ®): PLGA nanoparticles containing vitamin E TPGS. J Control Rel. 2003;86(1):33-48.
150. Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm. 2002;238(1-2):77-92.
151. Allémann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly (DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res. 1993;10(12):1732-37.
152. Derakhshandeh K, Erfan M, Dadashzadeh S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Sci. 2007;66(1):34-41.
153. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649-59.
154. da Silva AR, Inada NM, Rettori D, Baratti MO, Vercesi AE, Jorge RA. In vitro photodynamic activity of chloro(5,10,15,20-tetraphenylporphyrinato)indium(III) loaded-poly(lactide-co-glycolide) nanoparticles in LNCaP prostate tumour cells. J Photochem Photobiol Sci. 2009;94(2):101-12.
155. Snehalatha M, Venugopal K, Saha RN, Babbar AK, Sharma RK. Etoposide loaded PLGA and PCL nanoparticles II: biodistribution and pharmacokinetics after radiolabeling with Tc-99m. Drug Delivery. 2008;15(5):277-87.
156. Chen H, Gao J, Lu Y, Kou G, Zhang H, Fan L, Sun Z, Guo Y, Zhong Y. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Rel. 2008;128(3):209-16.
157. McCarron PA, Marouf WM, Quinn DJ, Fay F, Burden RE, Olwill SA, Scott CJ. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem. 2008;19(8):1561-9.
158. Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle biocon-jugates for breast cancer therapy. Biomaterials. 2009;30(29):5737-50.
159. Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BTS, Tjarks W, Barth RF, Claffey K, Backer JM. Vascular endothelial growth factor selectively targets boronated dendri-mers to tumor vasculature. Mol Cancer Therapeutics. 2005;4(9):1423-29.
160. Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labe-led nanoparticles. Int J Radiation Onc Bio Phy. 2004;58(4):1215-27.
161. Chen J, Wu H, Han D, Xie C. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett. 2006;231(2):169-75.
162. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577):2404-7.
163. Nasongkla N, Shuai X, Ai H, Weinberg BD, Pink J, Boothman DA, Gao J. CRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed. 2004;43(46):6323-7.
164. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta. 2008 Apr;1778(4):854-63.
165. Koby G, Ofra B, Dganit D, Marcelle M. Poly (D, L-lactide-co-glycolide acid) nanoparticles for DNA delivery: Waiving preparation complexity and increasing effi ciency. Peptide Science. 2007;85(5-6):379-91.
166. Chumakova OV, Liopo AV, Andreev VG, Cicenaite I, Evers BM, Chakrabarty S, Pappas TC, Ese-naliev RO. Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett. 2007;215(2):215-25.
167. Zou W, Liu C, Chen Z, Zhang N. Studies on bioadhesive PLGA nanoparticles: A promising gene delivery system for effi cient gene therapy to lung cancer. Int J Pharm. 2009;370(1-2):187-95.